Bienville Capital Management, LLC Gilead Sciences, Inc. Transaction History

Bienville Capital Management, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 16, 2020	SELL	$62.1 - $78.08 $290,007 - $364,633	-4,670 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$72.34 - $84.0 $337,827 - $392,280	4,670 New	4,670 $359,000
Q1 2020 May 15, 2020	SELL	$62.63 - $80.22 $469,725 - $601,650	-7,500 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$62.51 - $69.0 $43,444 - $47,955	-695 Reduced 8.48%	7,500 $475,000
Q2 2019 Aug 14, 2019	BUY	$61.87 - $69.38 $37,183 - $41,697	601 Added 7.91%	8,195 $554,000
Q1 2019 May 13, 2019	BUY	$62.53 - $70.05 $1,125 - $1,260	18 Added 0.24%	7,594 $494,000
Q4 2018 Feb 13, 2019	SELL	$60.54 - $79.0 $18,464 - $24,095	-305 Reduced 3.87%	7,576 $474,000
Q3 2018 Nov 14, 2018	BUY	$71.28 - $78.92 $1,140 - $1,262	16 Added 0.2%	7,881 $608,000
Q2 2018 Aug 08, 2018	SELL	$64.88 - $75.68 $3,957 - $4,616	-61 Reduced 0.77%	7,865 $557,000
Q1 2018 May 15, 2018	BUY	$72.84 - $88.8 $1,748 - $2,131	24 Added 0.3%	7,926 $598,000
Q4 2017 Feb 14, 2018	BUY	$71.15 - $83.52 $5,051 - $5,929	71 Added 0.91%	7,902 $566,000
Q3 2017 Nov 14, 2017	BUY	$72.11 - $85.47 $564,693 - $669,315	7,831	7,831 $634,000

1,923

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $113B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Bienville Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bienville Capital Management, LLC with notifications on news.